返回 
加入收藏
GLP-1受体激动剂致药物性肝损伤的文献病例分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | GLP-1受体激动剂致药物性肝损伤的文献病例分析 |
| TITLE： | Literature case analysis of drug-induced liver injury induced by GLP-1 receptor agonists |
| 摘要： | 目的 探讨胰高血糖素样肽-1受体激动剂（GLP-1RAs）致药物性肝损伤（DILI）的临床特征，为临床安全用药提供参考。方法以“GLP-1“”GLP-1RAs“”司美格鲁肽“”药物性肝损伤”等为检索词，检索PubMed、Embase、theCochraneLibrary、中国知网、万方数据和维普网，收集GLP-1RAs致DILI的相关文献并进行描述性分析。结果共纳入11篇文献，共计11例患者。11例患者中，男性4例（36.4%）、女性7例（63.6%）；患者年龄为17～64岁，其中50～65岁患者5例（45.5%）；6例用于治疗糖尿病，5例用于减重；10例患者伴有基础疾病；DILI发生时间最短的为用药后5d，最长约180d；GLP-1RAs致DILI以肝细胞损伤型为主（6例），严重程度包括重度（3例）、中度（6例）、轻度（2例），临床表现包括消化道症状、黄疸等；10例患者的DILI与GLP-1RAs的关联性为“很可能”，1例为“可能”；11例患者均经停药及（或）对症治疗后好转。结论GLP-1RAs致DILI相对集中于50～65岁人群，以女性为主，合并基础疾病的患者发生风险增加。临床应加强高危人群识别、用药教育（尤其是症状识别）等药学监护；出现相关症状时应立即停药，必要时给予保肝治疗，以保障患者的用药安全。 |
| ABSTRACT： | OBJECTIVE To investigate the clinical characteristics of drug-induced liver injury （DILI） induced by glucagon- like peptide-1 receptor agonists （GLP-1RAs）， and to provide a reference for safe clinical medication. METHODS Using search terms such as “GLP-1”“GLP-1RAs”“semaglutide” “drug-induced liver injury”， relevant studies from PubMed， Embase， the Cochrane Library， CNKI， Wanfang Data and VIP were retrieved. Descriptive analysis was performed on cases of DILI induced by GLP-1RAs. RESULTS A total of 11 studies， comprising 11 patients， were included. Among them， 4 were male （36.4%） and 7 were female （63.6%）. Patient ages ranged from 17 to 64 years； 5 patients （45.5%） were between 50 and 65 years old. Six patients were treated for diabetes， and five for weight loss. Ten patients had underlying diseases. The shortest time to the onset of DILI was 5 days after medication， while the longest was approximately 180 days. The DILIs induced by GLP-1RAs were mainly hepatocellular injury type （6 cases）； severity levels included severe （3 cases）， moderate （6 cases）， and mild （2 cases）. Gastrointestinal symptoms and jaundice were the most common clinical manifestations. The association between DILI and GLP- 1RAs was assessed as “probable” in 10 cases and “possible” in 1 case. All 11 patients improved after drug discontinuation and （or） corresponding treatment. CONCLUSIONS DILI induced by GLP-1RAs is relatively concentrated in patients aged 50-65， with a higher incidence in females. The risk may be further increased in patients with underlying diseases. Clinical use of these agents should enhance pharmaceutical care， including identification of high-risk populations and patient education （especially symptom recognition）. When relevant symptoms appear， the drug should be discontinued immediately， with liver-protective therapy initiated when necessary， to ensure patient safety of drug use. |
| 期刊： | 2025年第36卷第20期 |
| 作者： | 张梦华；朱颖；吴紫阳；王艳花；熊祥樽；缪丽燕 |
| AUTHORS： | ZHANG Menghua，ZHU Ying，WU Ziyang，WANG Yanhua，XIONG Xiangzun，MIAO Liyan |
| 关键字： | 胰高血糖素样肽-1受体激动剂；药物性肝损伤；文献病例分析；安全性 |
| KEYWORDS： | GLP-1 receptor agonists； drug-induced liver |
| 阅读数： | 4 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
